In this certified on-demand webcast, experts discuss the management of CLL/SLL therapy from frontline treatment to relapsed/refractory disease based on evidence from recent clinical trials and current NCCN guidelines as well as future directions to personalize and optimize patient care.
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia (CLL).
Join us for this dynamic, case-based, live symposium in collaboration with the NCCN to hear from an expert panel on current recommendations and emerging strategies for treating patients with CLL.
The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.
The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.
The goal of this program is to improve the knowledge, confidence, and competence of learners in the potential clinical applications of guideline-recommended therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Bruton’s tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape of B-cell malignancies. A thorough understanding of the mechanism of action (covalent vs. non-covalent), similarities and differences in their safety profile and management of specific treatment-related adverse events will enable clinicians to use these agents safely and effectively in routine clinical practice.
Facebook
X
LinkedIn
Forward